113403-10-4Relevant academic research and scientific papers
Temperature selective diastereo-recognition (TSD): Enantiomeric ibuprofen via environmentally benign selective crystallization
Bhattacharya, Apurba,Murphy, David
, p. 717 - 722 (2003)
Selective crystallization of ibuprofen/lysinate from 1 mol of (R,S)-(racemic) ibuprofen and ≤0.5 mol of (S)-lysine in aqueous ethanol affords either (S)-(+)-ibuprofen/(S)-lysinate or (R)-ibuprofen/(S)-lysinate (in preponderance) depending on the crystallization conditions. The previously unreported temperature selective diastereo-recognition (TSD) provides simple and efficient means to prepare either enantiomer of ibuprofen from (R,S)-ibuprofen utilizing the same commercially available inexpensive resolving agent, (S)-lysine. The unwanted enantiomeric ibuprofen could be recovered from the mother liquor and racemized by a simple, relatively waste-free thermal process. This racemization method when utilized in conjunction with the selective crystallization technology provides a simple, efficient, and eco-friendly means to prepare (S)-(+)-ibuprofen lysinate in an overall essentially quantitative yield. This technology also incorporates the fundamental principle of atom economy (via direct production of the preferred pharmaceutical salt of (S)-lysine).
Preparation method of lysinoprofen
-
Paragraph 0052-0122, (2021/01/29)
The invention belongs to the technical field of medicine preparation, and particularly relates to a preparation method of lysinoprofen. The preparation method comprises the following steps: concentrating lysine hydrochloride and then reacting lysine hydrochloride with ibuprofen, and decolorizing with activated carbon, and crystallizing with ethyl acetate to obtain the product. The method for preparing lysinoprofen is simple, does not need special equipment, and is simple and convenient to operate and good in process controllability; and the prepared finished product is good in quality and highin purity.
Pharmaceutical compositions containing the salts of S(+)-2-(4-isobutylphenyl)propionic acid with basic aminoacids
-
, (2008/06/13)
A pharmaceutical composition for oral use containing the salt of S(+)-2-(4-isobutylphenyl)propionic acid with a basic aminoacid selected between L-arginine and L-lysine is described.
Selective precipitation of α-aryl carboxylic acid salts
-
, (2008/06/13)
A process is provided whereby S(+)-ibuprofen or R(-)-ibuprofen L-lysinate salt is produced by selective precipitation from a mixture containing enantiomers of ibuprofen and L-lysine. The quantity of L-lysine is not more than about a molar equivalent of the quantity of one of the enantiomers in the ibuprofen enantiomeric mixture. Upon precipitation of one ibuprofen enantiomer from the mixture, the overall precipitate and reaction mixture can be held for a sufficient period of time at a second temperature to allow the first precipitate to redissolve into the reaction mixture and the other ibuprofen enantiomer to precipitate out of the mixture in the salt form. Optically active ibuprofen is racemized by being heated at 100° C. to 300° C. in the substantial absence of other materials.
Racemization of an enantomerically enriched α-aryl carboxylic acid
-
, (2008/06/13)
There is disclosed and claimed a process whereby S(+)-ibuprofen L-lysinate salt is produced by selective precipitation from a mixture containing enantiomers of ibuprofen and L-lysine. The quantity of L-lysine is not more than about a molar equivalent of the quantity of S(+)-ibuprofen in the ibuprofen enantiomeric mixture. The mother liquors after separating the above salt are enriched in R-ibuprofen which is racemized by a novel thermal racemization process and may then be recycled.
S(+)-ibuprofen-L-amino acid and S(+)-ibuprofen-D-amino acid as onset-hastened enhanced analgesics
-
, (2008/06/13)
S(+)-ibuprofen-L-amino acids and S(+)-ibuprofen-D-amino acids, substantially free of other ibuprofen-amino acid stereoisomers, give an onset-hastened, enhanced analgesic response in humans.
